Search

Author/Creator Matasar, M.

1. A PHASE I TRIAL OF 19‐28Z CAR‐T CELLS POST‐HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT‐ASCT) FOR RELAPSED AND REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL). (June 2017)

Authors:
Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; Matasar, M.; Curran, K.; Park, J.; Sadelain, M.; Brentjens, R.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
138
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019)

Authors:
Kim, W.S.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Budde, L.E.; Cheah, C.; Gregory, G.P.; Hong, J.; Ku, M.; Marlton, P.; Matasar, M.; Nastoupil, L.; Panizo, C.; Sehn, L.H.; Tzachanis, D.; Chu, W.; Hernandez, M.G.; Kwan, A.; Li, C.C.; Sison, I.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
567
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017)

Authors:
Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
36
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA. (12th June 2019)

Authors:
Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D.J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; Hamlin, P.; Zelenetz, A.; Matasar, M.; von Keudell, G.; Sermer, D.; Yahalom, J.; Dogan, A.; Seshan, V.; Younes, A.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
251
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA. (June 2017)

Authors:
Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P.; Horwitz, S.; Kumar, A.; Matasar, M.; Moskowitz, A.; Moskowitz, C.; Noy, A.; Palomba, M.; Portlock, C.; Sauter, C.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
229
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (12th June 2019)

Authors:
Batlevi, C.L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Moskowitz, A.J.; Moskowitz, C.H.; Noy, A.; Palomba, M.L.; Portlock, C.; Straus, D.; Boccomini, C.; Tucci, A.; Zelenetz, A.D.; Seshan, V.E.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL). (12th June 2019)

Authors:
Sehn, L.H.; Assouline, S.; Bartlett, N.L.; Bosch, F.; Diefenbach, C.M.; Flinn, I.; Hong, J.Y.; Kim, W.S.; Matasar, M.; Nastoupil, L.; Schuster, S.J.; Shadman, M.; Yoon, S.S.; Bender, B.; Chu, W.; Hernandez, G.M.; Kwan, A.; McCall, B.; Sison, I.; Wang, C.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
310
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY. (23rd June 2022)

Authors:
Matasar, M.; Bartlett, N. L.; Sehn, L. H.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L. J.; Wei, M. C.; Yin, S.; To, I.; Turner, D.; Huang, H.; Min, J.; Penuel, E.; Budde, L. E.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1016
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022)

Authors:
McMillan, A.; Haioun, C.; Sancho, J.-M.; Viardot, A.; Rodriguez Izquierdo, A.; Donato Martin, E. M.; García-Sancho, A. M.; Sandoval-Sus, J.; Tilly, H.; Vandenberghe, E.; Hirata, J.; Choudhry, P.; Chang, Y. M.; Musick, L.; Matasar, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1075
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗